Navidea Biopharmaceuticals, Inc.
NAVBDelisted Jan 16, 2024- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0000810509
Navidea Biopharmaceuticals, Inc. was delisted on Jan 16, 2024; its insiders filed their last Form 4 on Dec 5, 2023; 24 institutions reported holding it in 13F filings for Q3 2023, worth $225.8K in total; no superinvestor held it.
Holders of 5% or more of NAVB
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Navidea Biopharmaceuticals, Inc., largest stake first. The change is against the holder's previous filing.
No holder currently reports owning 5% or more of Navidea Biopharmaceuticals, Inc. on Schedule 13D or 13G.
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
16 Schedule 13D and 13G filings on Navidea Biopharmaceuticals, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Feb 5, 2024 | Scott John K Jr. | 13D/AOld format | – | – | – | SEC |
| Dec 21, 2023 | Scott John K Jr. | 13D/AOld format | – | – | – | SEC |
| Jul 5, 2023 | Scott John K Jr. | 13D/AOld format | – | – | – | SEC |
| Jul 3, 2023 | Bain Irwin Allen | 13G/AOld format | – | – | – | SEC |
| Jun 30, 2023 | Bain Irwin Allen | 13G/AOld format | – | – | – | SEC |
| Jun 16, 2023 | Scott John K Jr. | 13D/AOld format | – | – | – | SEC |
| Oct 6, 2022 | Bain Irwin Allen | 13GOld format | – | New | – | SEC |
| Sep 22, 2022 | Scott John K Jr. | 13D/AOld format | – | – | – | SEC |
| Sep 14, 2022 | Scott John K Jr. | 13D/AOld format | – | – | – | SEC |
| Sep 12, 2022 | Scott John K Jr. | 13D/AOld format | – | – | – | SEC |
| Apr 22, 2022 | Scott John K Jr. | 13D/AOld format | – | – | – | SEC |
| Jul 23, 2021 | Scott John K Jr. | 13D/AOld format | – | – | – | SEC |
| Jun 15, 2021 | Scott John K Jr. | 13D/AOld format | – | – | – | SEC |
| Apr 5, 2021 | Scott John K Jr. | 13D/AOld format | – | – | – | SEC |
| Mar 11, 2021 | Scott John K Jr. | 13D/AOld format | – | – | – | SEC |
| Mar 5, 2021 | Scott John K Jr. | 13D/AOld format | – | – | – | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Navidea Biopharmaceuticals, Inc. shares.
No Form 144 notices for Navidea Biopharmaceuticals, Inc. are on file.